Inactive Instrument

Kawasumi Laboratories, Incorporated

7703

JP3225800006

Medical Equipment, Supplies & Distribution

Kawasumi Laboratories, Incorporated's Equity Buyback announced on August 9, 2018 has expired with 1,200,000 shares for ¥860.4 million.

August 09, 2018

The company expired its plan on August 10, 2018.

Latest news about Kawasumi Laboratories, Incorporated

Sumitomo Bakelite Company Limited completed the acquisition of an additional 65.99% stake in Kawasumi Laboratories, Incorporated from a group of shareholders for ¥25.7 billion.	20-09-29	CI
Sumitomo Bakelite Company Limited made an offer to acquire the remaining 76.95% stake in Kawasumi Laboratories, Incorporated from a group of shareholders for ¥27 billion.	20-07-30	CI
Kawasumi Laboratories, Incorporated Reports Consolidated Earnings Results for Nine Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020	20-02-05	CI
Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 2, 2019; Provides Year End Dividend Guidance for the Year Ending March 31, 2020	19-11-07	CI
Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Provides Dividend Guidance for the Second Quarter of Fiscal 2020 and for the Year Ending March 31, 2020	19-08-07	CI
Sumitomo Bakelite Company Limited completed the acquisition of 20.8% stake in Kawasumi Laboratories, Incorporated.	19-05-15	CI
Sumitomo Bakelite Company Limited executed a capital and business alliance agreement to acquire 20.76% stake in Kawasumi Laboratories, Incorporated.	19-03-19	CI
Tranche Update on Kawasumi Laboratories, Incorporated's Equity Buyback Plan announced on August 9, 2018.	18-08-09	CI
Kawasumi Laboratories, Incorporated's Equity Buyback announced on August 9, 2018 has expired with 1,200,000 shares for ¥860.4 million.	18-08-09	CI
Kawasumi Laboratories, Incorporated announces an Equity Buyback for 1,300,000 shares, representing 5.96% for ¥932.1 million.	18-08-09	CI
Kawasumi Laboratories, Incorporated authorizes a Buyback Plan.	18-08-08	CI
Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Year Ended March 31, 2018; Announces Dividend for the Year Ended March 31, 2018, Payable on June 22, 2018; Provides Earnings Guidance or the Year Ending March 31, 2019; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2019	18-05-14	CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Earnings and Dividend Guidance for the Year Ending March 31, 2018	18-02-07	CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Full Year of Fiscal Year Ending March 31, 2018	17-11-08	CI
Japanese Organization for Medical Device Development, Inc. announced that it has received ¥610 million in funding from Sumitomo Bakelite Company Limited, Kawasumi Laboratories, Incorporated	17-10-22	CI
Kawasumi Laboratories Inc. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Six Months Ending September 30, 2017 and Full Year Ending March 31, 2018; Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2018	17-08-08	CI
Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Year Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2017 and Full Year Ending March 31, 2018; Announces Dividend for the Year Ended March 31, 2017, Payable on June 23, 2017; Provides Dividend Guidance for the Second Quarter of Fiscal 2018 and for the Year Ending March 31, 2018	17-05-10	CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the nine Months Ended December 31, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017; Provides Dividend Guidance for the Year End of Fiscal Year 2017	17-02-08	CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017; Announces Dividend for the Second Quarter End of Fiscal Year 2017, Payable on December 5, 2016; Provides Dividend Guidance for the Year End of Fiscal Year 2017	16-11-09	CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2016 and Full Year of Fiscal Year Ending March 31, 2017	16-08-09	CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Year Ended March 31, 2016; Declares Dividend for the Year Ended March 31, 2016, Payable on June 24, 2016; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2016 and Full Year Ending March 31, 2017; Provides Dividend Guidance for the Year Ending March 31, 2017	16-05-23	CI
Tranche Update on Kawasumi Laboratories Inc.'s Equity Buyback Plan announced on November 11, 2015.	16-02-10	CI
Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Third Quarter Ended December 2015	16-02-09	CI
Kawasumi Laboratories Inc.'s Equity Buyback announced on November 11, 2015, has expired with 1,051,400 shares, representing 4.6% for ¥999.95 million.	16-02-08	CI
Tranche Update on Kawasumi Laboratories Inc.'s Equity Buyback Plan announced on November 11, 2015.	16-02-02	CI

Chart Kawasumi Laboratories, Incorporated

Duration

Period

Chart Kawasumi Laboratories, Incorporated

More charts

Kawasumi Laboratories, Incorporated is a Japan-based company engaged in the manufacture and sale of medical equipment and products. The Company operates in two business segments. The Blood- and Blood Vessel-related segment is engaged in the manufacture and sale of blood bags, blood collecting kits, blood transfer sets and others. The Extracorporeal Circulation segment mainly provides dialyzers, blood circuits, arterial venous fistula (AVF) needles, blood filters, physiological saline, artificial heart lung circuits and others.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-2.92%	185B
MEDTRONIC PLC	-3.80%	107B
BECTON, DICKINSON AND COMPANY	-5.48%	67.55B
DEXCOM, INC.	+11.22%	54.6B
CENCORA, INC.	+16.74%	47.42B
HOYA CORPORATION	+3.86%	42.24B
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	28.24B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.42B
TERUMO CORPORATION	+12.40%	25.66B

Other Medical Equipment, Supplies & Distribution